Should I Buy PSNL? PSNL 2026 Analysis

Should You Buy Personalis Inc (PSNL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

9.970

1 Day change

-0.20%

52 Week Range

11.500

Analysis Updated At

2026/01/26

Personalis Inc (PSNL) is a good buy for a beginner investor with a long-term investment horizon and $50,000-$100,000 available for investment. The recent Medicare reimbursement approval for its NeXT Personal test is a significant positive catalyst, and analysts have raised price targets significantly. While the company's financials show declining revenue and profitability, the reimbursement approval derisks future clinical revenue and positions the company for growth. Technical indicators are bullish, and options data suggests a mixed but slightly cautious sentiment. Given the investor's profile and the current data, this is a reasonable long-term investment opportunity.

Technical Analysis

The MACD is positive and contracting, indicating bullish momentum. The RSI is neutral at 58.499, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at $11 and $11.857, with support at $8.227 and $7.37. The stock is trading above its pivot point of $9.614, suggesting upward potential.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

The low open interest put-call ratio indicates bullish sentiment, but the higher option volume put-call ratio suggests cautious short-term sentiment. Implied volatility is high at 228.33, indicating significant price movement expectations.

Technical Summary

Sell

Buy

Positive Catalysts

Medicare reimbursement approval for NeXT Personal test, effective retroactively, with high reimbursement rates. Analysts have significantly raised price targets, citing this as a major win that derisks clinical revenue. Bullish technical indicators and a 7.04% chance of price increase in the next month.

Neutral/Negative Catalysts

Declining financial performance in Q3 2025, with revenue, net income, EPS, and gross margin all showing significant YoY declines. No recent insider or hedge fund activity, and no congress trading data available.

Financial Performance

In Q3 2025, revenue dropped by -43.62% YoY to $14.495M, net income dropped by -44.61% YoY to -$21.652M, EPS dropped by -62.50% YoY to -$0.24, and gross margin dropped by -61.20% YoY to 13.2%. The financial performance is weak but overshadowed by the positive reimbursement news.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are bullish, with multiple firms raising price targets significantly. Morgan Stanley raised the target to $9, H.C. Wainwright to $13, Guggenheim to $12, and Lake Street to $11. Analysts view the Medicare reimbursement approval as a major positive catalyst for the company.

7 Analyst Rating

Wall Street analysts forecast PSNL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSNL is 11.17 USD with a low forecast of 10 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 9.990

Low

Averages

11.17

High

Current: 9.990

Low

Averages

11.17

High

Guggenheim

Subbu Nambi

maintain

$12 -> $13

AI Analysis

2026-01-26

New

Reason

Guggenheim

Subbu Nambi

Price Target

$12 -> $13

AI Analysis

2026-01-26

New

maintain

Reason

Guggenheim analyst Subbu Nambi raised the firm's price target on Personalis to $13 from $12 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.

Morgan Stanley

Equal Weight

maintain

$5 -> $9

2025-11-11

Reason

Morgan Stanley

Price Target

$5 -> $9

2025-11-11

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Personalis to $9 from $5 and keeps an Equal Weight rating on the shares after the company announced Medicare coverage of its ultrasensitive NeXT Personal test for surveillance of cancer recurrence in breast cancer patients.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PSNL

Unlock Now

PSNL Should I Buy

PSNL Should I Buy

Should You Buy Personalis Inc (PSNL) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch